Cargando…

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden

Detalles Bibliográficos
Autores principales:	Kristófl, R., Bodegard, J., Ritsinger, V., Thuresson, M., Nathanson, D., Nyström, T., Norhammar, A., Eriksson, J.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014366/ http://dx.doi.org/10.1016/j.diabres.2023.110543

Ejemplares similares

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
por: Nathanson, David, et al.
Publicado: (2017)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Shape the future of diabetes at the IDF World Diabetes Congress 2022
Publicado: (2022)

Bariatric surgery: an IDF statement for obese Type 2 diabetes
por: Dixon, J B, et al.
Publicado: (2011)

Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes
por: Ritsinger, Viveca, et al.
Publicado: (2021)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

IDF2022-0354 The impact of COVID-19 lockdown on the changes in glycated hemoglobin in patients with type 2 diabetic in Taiwan
por: Cheng, Y.C.
Publicado: (2023)

IDF2022-0928 Impact of the COVID-19 Pandemic on Type 2 Diabetes Incidence in Canada: Will the Pandemic shift the Diabetes Trajectory?
por: Fazli, G., et al.
Publicado: (2023)

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry
por: Ritsinger, Viveca, et al.
Publicado: (2020)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

ADPKD: Prototype of Cardiorenal Syndrome Type 4
por: Virzì, Grazia Maria, et al.
Publicado: (2010)

Advances in the Pathogenesis of Cardiorenal Syndrome Type 3
por: Clementi, Anna, et al.
Publicado: (2015)

The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

IDF2022-1189 Glucose control in men and women with diabetes before and during the COVID-19 pandemic
por: Harding, J., et al.
Publicado: (2023)

IDF2022-0286 Presence of SARS-CoV-2 antibodies in asymptomatic type 1 diabetes; is there any association between glycemic control
por: Fawwad, A., et al.
Publicado: (2023)

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
por: Jernberg, Tomas, et al.
Publicado: (2019)

Acquired hemophilia complicated by cardiorenal syndrome type 3
por: Sharma, Rakesh, et al.
Publicado: (2013)

Kidney-Related Outcome in Cardiorenal Syndrome Type 3
por: Drubel, Kim, et al.
Publicado: (2022)

IDF2022-0579 Post COVID-19 diabetes project: Intensive cardio-renal-metabolic management for people living with type 2 diabetes (T2D)
por: Ahmad, E., et al.
Publicado: (2023)

The Heroes of the I.D.F.
por: Gotweter, Y.
Publicado: (1967)

IDF2022-0819 Returning to normal after corona-virus pandemia, views of people with diabetes in Finland
por: Koski, S.
Publicado: (2023)

Cardiorenal syndrome type 2: from diagnosis to optimal management
por: De Vecchis, Renato, et al.
Publicado: (2014)

Panoramic Dominance of the Immune System in Cardiorenal Syndrome Type I
por: Peesapati, Venkata Sri Ramani, et al.
Publicado: (2020)

Evidence based review of management of cardiorenal syndrome type 1
por: Ong, Leong Tung
Publicado: (2021)

Renal injury in cardiorenal syndrome type 1 is mediated by albumin
por: Funahashi, Yoshio, et al.
Publicado: (2022)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

IDF21-0109 Coagulation Disorders in Type 2 Diabetes Mellitus Patients with COVID-19
por: Syukur, C., et al.
Publicado: (2022)

IDF21-0683 Social and emotional impact of the COVID-19 pandemic in people with Type 1 Diabetes
por: Rodriguez Montalvan, B.F., et al.
Publicado: (2022)

Acute kidney injury in cardiorenal syndrome type 1: a meta-analysis
por: Vandenberghe, W, et al.
Publicado: (2014)

IDF21-0463 Type 1 Diabetes with insulin resistance following SARS-CoV-2 infection
por: Veríssimo, D., et al.
Publicado: (2022)

IDF21-0616 Observational study on covid 19 and type 1 diabetes in the Chronic Care Center Lebanon
por: Maalouf Nawfal, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7rdp6vrj8qvihn9anl6sv19cau